Gujarat Inject (Kerala) Ltd
₹ 114
-0.26%
05 Jun
- close price
About
Incorporated in 1991, Gujarat Inject Kerala Ltd manufactures pharmaceutical products
Key Points
- Market Cap ₹ 167 Cr.
- Current Price ₹ 114
- High / Low ₹ 120 / 19.0
- Stock P/E 92.4
- Book Value ₹ 8.07
- Dividend Yield 0.00 %
- ROCE 22.9 %
- ROE 16.6 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Debtor days have improved from 130 to 63.8 days.
Cons
- Stock is trading at 14.2 times its book value
- Company has a low return on equity of 12.1% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.02 | 1.57 | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 | 0.17 | 5.79 | 19.05 | 36.32 | |
| 0.00 | 0.02 | 1.56 | 0.07 | 0.03 | 0.01 | 0.13 | 0.07 | 0.54 | 5.74 | 17.98 | 34.02 | |
| Operating Profit | 0.00 | 0.00 | 0.01 | -0.07 | -0.03 | -0.01 | -0.12 | -0.05 | -0.37 | 0.05 | 1.07 | 2.30 |
| OPM % | 0.00% | 0.64% | -1,200.00% | -250.00% | -217.65% | 0.86% | 5.62% | 6.33% | ||||
| 0.00 | 2.30 | 0.00 | 0.05 | 0.02 | 0.01 | 0.01 | 0.05 | 0.43 | 0.06 | 0.18 | 0.20 | |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.00 | 2.30 | 0.01 | -0.02 | -0.01 | 0.00 | -0.11 | 0.00 | 0.06 | 0.11 | 1.25 | 2.50 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 16.67% | 18.18% | 19.20% | 27.60% | |||
| 0.00 | 2.30 | 0.01 | -0.02 | -0.01 | 0.00 | -0.11 | 0.00 | 0.04 | 0.08 | 1.02 | 1.81 | |
| EPS in Rs | 0.00 | 4.69 | 0.02 | -0.04 | -0.02 | 0.00 | -0.22 | 0.00 | 0.08 | 0.07 | 0.70 | 1.24 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 112% |
| 5 Years: | 415% |
| 3 Years: | 498% |
| TTM: | 91% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 79% |
| 3 Years: | 256% |
| TTM: | 77% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 113% |
| 1 Year: | 377% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 12% |
| Last Year: | 17% |
Balance Sheet
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4.88 | 4.88 | 4.88 | 4.88 | 4.88 | 4.88 | 4.88 | 4.88 | 4.88 | 11.29 | 14.63 | 14.63 |
| Reserves | -7.95 | -5.64 | -5.64 | -5.66 | -5.66 | -5.66 | -5.77 | -5.76 | -5.72 | -2.75 | -4.62 | -2.81 |
| 2.86 | 0.56 | 0.57 | 0.59 | 0.59 | 0.59 | 0.69 | 0.73 | 0.61 | 0.00 | 0.00 | 0.00 | |
| 0.38 | 0.36 | 0.20 | 0.21 | 0.20 | 0.20 | 0.22 | 0.22 | 0.53 | 0.15 | 1.94 | 24.85 | |
| Total Liabilities | 0.17 | 0.16 | 0.01 | 0.02 | 0.01 | 0.01 | 0.02 | 0.07 | 0.30 | 8.69 | 11.95 | 36.67 |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 20.76 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 0.17 | 0.16 | 0.01 | 0.02 | 0.01 | 0.01 | 0.02 | 0.07 | 0.30 | 8.69 | 11.95 | 15.91 | |
| Total Assets | 0.17 | 0.16 | 0.01 | 0.02 | 0.01 | 0.01 | 0.02 | 0.07 | 0.30 | 8.69 | 11.95 | 36.67 |
Cash Flows
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 | -0.11 | 0.00 | 0.05 | -6.03 | -1.55 | 21.22 | |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.18 | -20.57 | |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.10 | 0.00 | 0.00 | 8.88 | -1.53 | 0.00 | |
| Net Cash Flow | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 | 2.86 | -2.89 | 0.65 |
| Free Cash Flow | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 | -0.11 | 0.00 | 0.05 | -6.03 | -1.55 | 0.46 |
| CFO/OP | 0% | 14% | 0% | 0% | 92% | 0% | -16% | -12,020% | -122% | 953% |
Ratios
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 187.86 | 137.57 | 63.81 | ||||
| Inventory Days | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 187.86 | 137.57 | 63.81 | ||||
| Working Capital Days | -8,395.00 | -106.94 | -17,520.00 | -9,490.00 | -1,545.88 | 354.91 | 153.47 | -140.29 | ||||
| ROCE % | 2.65% | 13.48% | 22.89% |
Insights
In beta| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Permanent Employees Number |
|
|||||||||||
| Revenue from Trading (Sales of Fabric/Textiles) INR Lacs |
||||||||||||
| Business Activity Segment (Textile Trading) Percentage Contribution |
||||||||||||
Requires Premium
Requires Premium
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
25 May - FY26 revenue rose 91% to Rs.36.32 crore; net profit up 78%; solar orders worth Rs.14.49 crore secured.
- Results - Financial Results For 31/03/2026 20 May
-
Board Meeting Outcome for Outcome Of The Board Meeting Held On Wednesday, 20Th May, 2026 And Submission Of Audited Financial Results (Standalone) For The Fourth Quarter And Year Ended On 31St March, 2026
20 May - 20 May 2026 board approved FY26 audited standalone results; profit ₹181.41 lakh, unmodified audit opinion.
-
Announcement under Regulation 30 (LODR)-Change in Directorate
16 May - Murli Shivshankaran Nair resigned as MD and chairman; Deepak Diwan Bachwani appointed Whole Time Director and chairman effective 16 May 2026.
-
Announcement under Regulation 30 (LODR)-Resignation of Chairman and Managing Director
16 May - Murli Shivshankaran Nair resigned as MD and chairman; Deepak Diwan Bachwani appointed Whole Time Director and chairman effective 16 May 2026.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2011
from bse
-
Financial Year 2007
from bse
-
Financial Year 2005
from bse
-
Financial Year 2004
from bse
Business Overview:[1]
Company is jointly promoted by Kerala State Industrial Development Corporation Limited,
a wholly owned subsidiary of Government of Kerala and Gujarat Inject Limited. Company manufactures and sells bulk drugs, formulations, chemicals, medicinal preparation, intravenous fluids, infusion and transfusion solutions, vitamin and non vitamin tablets, capsules, liquids and also medical equipment viz., disposable plastic bottles, surgical sets, infusion and transfusion sets, disposable syringes, diagnostic kits, etc.